Reni J. Benjamin
Stock Analyst at Citizens
(1.79)
# 3,478
Out of 5,182 analysts
22
Total ratings
30%
Success rate
-3.55%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Reni J. Benjamin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BCAX Bicara Therapeutics | Reiterates: Market Outperform | $31 | $20.85 | +48.68% | 2 | Mar 31, 2026 | |
| IMMX Immix Biopharma | Reiterates: Market Outperform | $23 | $8.59 | +167.75% | 1 | Mar 27, 2026 | |
| LYEL Lyell Immunopharma | Initiates: Market Outperform | $34 | $21.57 | +57.63% | 1 | Mar 9, 2026 | |
| IOVA Iovance Biotherapeutics | Upgrades: Market Outperform | $5 | $3.30 | +51.52% | 2 | Mar 3, 2026 | |
| IMMP Immutep | Initiates: Market Outperform | $10 | $0.36 | +2,677.78% | 2 | Feb 23, 2026 | |
| SMMT Summit Therapeutics | Reiterates: Market Outperform | $40 | $18.69 | +114.02% | 4 | Jan 30, 2026 | |
| ZYME Zymeworks | Initiates: Market Outperform | $32 | $25.84 | +23.84% | 1 | Dec 3, 2025 | |
| ONC BeOne Medicines AG | Maintains: Market Outperform | $348 → $396 | $302.49 | +30.91% | 1 | Nov 7, 2025 | |
| SANA Sana Biotechnology | Maintains: Market Outperform | $5 → $8 | $3.22 | +148.45% | 1 | Oct 30, 2025 | |
| KURA Kura Oncology | Reiterates: Market Outperform | $24 | $8.49 | +182.69% | 2 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $63.72 | - | 1 | Aug 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $4 → $3 | $1.04 | +188.46% | 1 | Aug 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $4 → $3 | $3.68 | -18.48% | 1 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $5.65 | - | 1 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $22 → $10 | $4.89 | +104.50% | 1 | Aug 12, 2025 |
Bicara Therapeutics
Mar 31, 2026
Reiterates: Market Outperform
Price Target: $31
Current: $20.85
Upside: +48.68%
Immix Biopharma
Mar 27, 2026
Reiterates: Market Outperform
Price Target: $23
Current: $8.59
Upside: +167.75%
Lyell Immunopharma
Mar 9, 2026
Initiates: Market Outperform
Price Target: $34
Current: $21.57
Upside: +57.63%
Iovance Biotherapeutics
Mar 3, 2026
Upgrades: Market Outperform
Price Target: $5
Current: $3.30
Upside: +51.52%
Immutep
Feb 23, 2026
Initiates: Market Outperform
Price Target: $10
Current: $0.36
Upside: +2,677.78%
Summit Therapeutics
Jan 30, 2026
Reiterates: Market Outperform
Price Target: $40
Current: $18.69
Upside: +114.02%
Zymeworks
Dec 3, 2025
Initiates: Market Outperform
Price Target: $32
Current: $25.84
Upside: +23.84%
BeOne Medicines AG
Nov 7, 2025
Maintains: Market Outperform
Price Target: $348 → $396
Current: $302.49
Upside: +30.91%
Sana Biotechnology
Oct 30, 2025
Maintains: Market Outperform
Price Target: $5 → $8
Current: $3.22
Upside: +148.45%
Kura Oncology
Oct 20, 2025
Reiterates: Market Outperform
Price Target: $24
Current: $8.49
Upside: +182.69%
Aug 22, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $63.72
Upside: -
Aug 21, 2025
Maintains: Market Outperform
Price Target: $4 → $3
Current: $1.04
Upside: +188.46%
Aug 18, 2025
Maintains: Market Outperform
Price Target: $4 → $3
Current: $3.68
Upside: -18.48%
Aug 13, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $5.65
Upside: -
Aug 12, 2025
Maintains: Market Outperform
Price Target: $22 → $10
Current: $4.89
Upside: +104.50%